Intrathecal Pumps Market by Pump Type (External Pumps, Implantable Pumps), Drug Type (Baclofen, Local Anesthetics, Opioids), Therapy Area, End User - Global Forecast 2025-2032
Description
The Intrathecal Pumps Market was valued at USD 1.62 billion in 2024 and is projected to grow to USD 1.73 billion in 2025, with a CAGR of 8.64%, reaching USD 3.15 billion by 2032.
Establishing the contemporary clinical context for intrathecal pump therapies where device innovation, clinical demand, and regulatory focus converge to shape adoption decisions
Intrathecal pumps represent a sophisticated intersection of neuromodulation engineering, pharmacotherapy management, and specialized clinical pathways, and this introduction frames the contemporary environment in which those therapies operate. The landscape is defined by incremental device innovation, expanding therapeutic indications, and intensified scrutiny around safety and long-term device performance. Clinicians and health systems are balancing procedural complexity against quality-of-life gains for patients living with refractory spasticity and complex chronic pain conditions, driving heightened interest in evidence that links device selection to meaningful clinical outcomes.
Concurrent advances in materials science, catheter design, and drug delivery algorithms are enabling more precise dosing and reduced procedural burden, while regulatory bodies continue to refine pathways for device approvals and post-market surveillance. As a result, procurement leaders and clinical champions must account for device interoperability, refill logistics, and training demands when integrating intrathecal therapy into care pathways. This introduction establishes the vantage point for subsequent discussion by highlighting how converging pressures-clinical demand, technological refinement, and system-level expectations-are shaping adoption decisions and the priorities of diverse stakeholders across hospitals, specialty clinics, and ambulatory surgical settings.
How recent technological advances, evolving payer expectations, and cross-sector partnerships are reshaping clinical delivery models and competitive dynamics in intrathecal therapy
The intrathecal pump landscape is undergoing transformative shifts driven by technological maturation, evolving clinical practice, and new stakeholder expectations. Device engineering improvements are reducing implantation complexity and enhancing the precision of intrathecal dosing, while manufacturers increasingly integrate diagnostics and telemetric capabilities to support remote monitoring and proactive therapy adjustments. These capabilities are prompting clinicians to reassess long-term management models and to explore bundled care pathways that emphasize continuity and reduced emergency interventions.
At the same time, payer expectations and value-based care initiatives are encouraging stakeholders to emphasize outcomes beyond short-term pain relief, including functional gains and reductions in ancillary healthcare utilization. This is accelerating collaboration between device makers, pharma developers, and health systems to develop evidence packages that demonstrate real-world benefit. Additionally, the competitive environment is opening to newer entrants focused on niche opportunities, such as battery longevity optimization, minimally invasive implant techniques, and adjunctive software services. Collectively, these shifts are steering the sector toward integrated solution models where device performance, clinician training, and service delivery converge to determine clinical and commercial success.
Observed supply chain realignments and procurement responses following tariff-driven cost and logistics pressures affecting components, manufacturing, and device availability
Recent tariff measures implemented in the United States have produced a tangible ripple effect across supply chains that support intrathecal pump manufacturing and distribution, with impacts observed across sourcing, procurement, and operational planning. Manufacturers that historically relied on cross-border component sourcing have had to re-evaluate supplier footprints in response to increased import costs and longer lead times. In some cases, this has accelerated the onboarding of alternative suppliers closer to key manufacturing hubs or prompted the requalification of legacy domestic suppliers to preserve continuity of production.
Procurement teams and hospital supply chains have adjusted purchasing strategies to mitigate near-term cost pressures, prioritizing inventory buffers and negotiating more flexible contractual terms with vendors. At the clinical delivery level, facilities have re-examined device selection criteria against total acquisition and servicing considerations, seeking devices with lower refill frequency or simplified maintenance protocols that reduce cumulative procedural burden. Regulatory compliance and customs procedures have also required tighter coordination between manufacturers and logistics partners to prevent delays in device availability. Taken together, these dynamics underscore the importance of supply chain resilience, diversified sourcing strategies, and operational contingency planning to maintain consistent access to intrathecal therapies for patients and providers.
Deep segmentation-driven insights linking pump types, therapeutic agents, care settings, and clinical indications to inform targeted clinical strategies and product design priorities
Segmentation analysis provides a structured lens to interpret clinical use patterns, procurement priorities, and product development focus across intrathecal therapy categories. Based on Pump Type, market is studied across External Pumps and Implantable Pumps, and each pump class follows distinct clinical pathways: external pumps are frequently used in trialing and short-term therapeutic scenarios, enabling rapid titration and reversible testing, while implantable pumps are favored for chronic administration where continuous, long-term control is required and device longevity, refill scheduling, and implantation logistics become central determinants of clinical suitability.
Based on Drug Type, market is studied across Baclofen, Local Anesthetics, and Opioids, and therapeutic selection is influenced by the underlying neurologic or pain condition, safety profile, and compatibility with pump delivery parameters. Baclofen remains the pharmacologic mainstay for severe spasticity due to its targeted action at spinal GABA receptors, while local anesthetics and opioids serve differentiated roles in managing localized nociceptive and neuropathic pain, each requiring tailored dosing regimens and monitoring strategies. Based on Therapy Area, market is studied across Pain Management and Spasticity Management. The Pain Management is further studied across Cancer Pain and Chronic Noncancer Pain. The Spasticity Management is further studied across Cerebral Palsy, Multiple Sclerosis, and Spinal Cord Injury. These therapeutic distinctions map to unique clinical pathways, with cancer pain often prioritizing rapid symptom control and palliative considerations, whereas chronic noncancer pain and spasticity conditions emphasize long-term functional outcomes, device tolerability, and integration with rehabilitation services.
Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, and each care setting imposes different operational requirements and value propositions. Ambulatory surgical centers may prioritize streamlined implantation protocols and rapid turnover, hospitals often require comprehensive perioperative support and complex case management, and specialty clinics emphasize multidisciplinary follow-up, titration expertise, and coordinated refill services. Together, these segmentation dimensions reveal where product design, service delivery, and stakeholder engagement must be aligned to meet the clinical and operational demands of diverse use cases.
Regional adoption dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape clinical access and manufacturing strategies
Regional dynamics exert a strong influence on clinical adoption patterns, regulatory approaches, and manufacturing strategies across intrathecal therapies. In the Americas, healthcare systems exhibit a mix of high-volume tertiary centers and a growing network of outpatient surgical facilities, and adoption is frequently shaped by reimbursement pathways, clinician training availability, and a strong emphasis on real-world evidence to support therapeutic choices. The Americas also house significant medtech manufacturing capability, which can facilitate closer coordination between development teams and clinical partners.
Europe, Middle East & Africa presents a heterogeneous environment where country-level regulatory frameworks and payer structures create varied adoption trajectories. In parts of Europe, centralized health technology assessment and long-standing specialty centers for neuromodulation support nuanced evidence development, whereas other jurisdictions within the region may emphasize cost-containment and centralized procurement strategies. Middle Eastern and African markets show pockets of high adoption in well-resourced centers alongside growing interest in capacity building, clinician training, and locally adapted care models.
Asia-Pacific encompasses a broad spectrum of health system maturity, with rapidly expanding clinical infrastructures in several markets, increasing local manufacturing investments, and growing clinical research activity. Regulatory harmonization initiatives and the scaling of specialty clinics are enabling broader patient access in many urban centers. Across all regions, stakeholders are increasingly focused on ensuring that device support networks, clinician education, and supply continuity are robust enough to sustain long-term therapy delivery.
How differentiated device features, integrated service models, and strategic partnerships are defining competitive advantage among manufacturers and new entrants in intrathecal therapy
Competitive positioning in the intrathecal therapy space is being defined by a mix of established medical device firms, specialized device innovators, and adjacent life sciences players seeking to expand into integrated therapy solutions. Leading organizations are investing in end-to-end value propositions that combine device hardware, software-enabled monitoring, and clinician education services to differentiate on total cost of care and long-term patient management. Strategic partnerships with pharmaceutical developers are also increasingly common, enabling coordinated development of device-drug combinations and shared clinical evidence initiatives.
New entrants are targeting niche technical improvements, such as refined catheter fixation systems, extended battery life, or simplified refill interfaces that reduce procedural complexity. Contract manufacturing organizations and regional suppliers are playing a larger role in enabling flexible production footprints, particularly where tariff pressures or logistics constraints have elevated the importance of nearshoring. Intellectual property portfolios that protect key delivery mechanisms and software algorithms are central competitive assets, while real-world evidence programs and registry participation are emerging as critical tools for demonstrating comparative performance and safety to clinicians and payers. Overall, companies that combine technical differentiation with robust service models and evidence generation are positioned to secure durable clinical partnerships.
Practical strategic priorities for device manufacturers and healthcare leaders to strengthen resilience, clinical value, and adoption of intrathecal therapies across care settings
Industry leaders should prioritize practical, patient-centered strategies that strengthen resilience, clinical value, and long-term adoption. First, supply chain diversification and nearshoring of critical components should be pursued to mitigate exposure to tariff-driven disruptions and to reduce lead time variability. Second, investment in device features that reduce clinical friction-such as longer refill intervals, simplified programming interfaces, and enhanced telemetry-will meaningfully improve adoption in both ambulatory and hospital settings.
Third, manufacturers and clinical leaders should collaborate to generate robust real-world evidence focused on functional outcomes, safety over longitudinal follow-up, and healthcare utilization metrics that resonate with payers. Fourth, embedding structured clinician training programs and certified centers of excellence models will accelerate safe adoption and improve consistency of patient outcomes. Fifth, consider flexible commercial models that align pricing and service delivery with demonstrated value, including outcome-linked contracting where feasible. Finally, continued attention to regulatory engagement and post-market surveillance will be essential to maintain trust, rapidly address safety signals, and support iterative device improvements that reflect clinician feedback and patient needs.
A robust multi-method research approach combining expert interviews, clinical literature review, regulatory analysis, and data triangulation to ensure reliable and actionable insights
The research underpinning this executive synthesis was developed through a multi-method approach that integrates primary stakeholder engagement with rigorous secondary evidence synthesis. Primary inputs included structured interviews with clinicians experienced in intrathecal therapy, procurement and supply chain professionals, regulatory specialists, and product development leaders. These conversations provided detailed insights into procedural workflows, device selection criteria, and operational barriers to adoption.
Secondary research encompassed a systematic review of peer-reviewed clinical literature, device regulatory filings, clinical guidelines, and device registries to contextualize clinical outcomes and safety profiles. Data triangulation was applied to reconcile differing perspectives and to validate recurring themes. Quality control procedures included cross-validation of interview insights against documented clinical evidence and regulatory records, and findings were peer-reviewed within the research team to ensure coherence and robustness. Throughout, the methodology emphasized transparency, reproducibility, and the synthesis of actionable intelligence tailored to decision-makers engaged in device development, clinical program design, and supply chain planning.
Synthesis of core conclusions emphasizing alignment of device innovation, clinician training, and supply chain resilience to sustain long-term intrathecal therapy delivery
Intrathecal pump therapies occupy a distinct clinical niche that demands coordinated attention to device performance, clinical training, and operational logistics. Advances in device engineering and the integration of remote monitoring are creating opportunities to improve patient outcomes while reshaping how care pathways are structured. At the same time, external pressures such as tariff-driven supply chain adjustments and evolving payer expectations are prompting stakeholders to re-evaluate sourcing, procurement, and evidence generation strategies.
The synthesis presented here underscores that successful adoption hinges on aligning product innovation with real-world clinical needs, investing in clinician education and service models, and building resilient supply chains capable of responding to policy and logistical shifts. Decision-makers who proactively address these dimensions can better position their organizations to deliver consistent, high-quality intrathecal care and to navigate the complex interplay of clinical, regulatory, and commercial forces that will influence long-term therapy sustainability.
Note: PDF & Excel + Online Access - 1 Year
Establishing the contemporary clinical context for intrathecal pump therapies where device innovation, clinical demand, and regulatory focus converge to shape adoption decisions
Intrathecal pumps represent a sophisticated intersection of neuromodulation engineering, pharmacotherapy management, and specialized clinical pathways, and this introduction frames the contemporary environment in which those therapies operate. The landscape is defined by incremental device innovation, expanding therapeutic indications, and intensified scrutiny around safety and long-term device performance. Clinicians and health systems are balancing procedural complexity against quality-of-life gains for patients living with refractory spasticity and complex chronic pain conditions, driving heightened interest in evidence that links device selection to meaningful clinical outcomes.
Concurrent advances in materials science, catheter design, and drug delivery algorithms are enabling more precise dosing and reduced procedural burden, while regulatory bodies continue to refine pathways for device approvals and post-market surveillance. As a result, procurement leaders and clinical champions must account for device interoperability, refill logistics, and training demands when integrating intrathecal therapy into care pathways. This introduction establishes the vantage point for subsequent discussion by highlighting how converging pressures-clinical demand, technological refinement, and system-level expectations-are shaping adoption decisions and the priorities of diverse stakeholders across hospitals, specialty clinics, and ambulatory surgical settings.
How recent technological advances, evolving payer expectations, and cross-sector partnerships are reshaping clinical delivery models and competitive dynamics in intrathecal therapy
The intrathecal pump landscape is undergoing transformative shifts driven by technological maturation, evolving clinical practice, and new stakeholder expectations. Device engineering improvements are reducing implantation complexity and enhancing the precision of intrathecal dosing, while manufacturers increasingly integrate diagnostics and telemetric capabilities to support remote monitoring and proactive therapy adjustments. These capabilities are prompting clinicians to reassess long-term management models and to explore bundled care pathways that emphasize continuity and reduced emergency interventions.
At the same time, payer expectations and value-based care initiatives are encouraging stakeholders to emphasize outcomes beyond short-term pain relief, including functional gains and reductions in ancillary healthcare utilization. This is accelerating collaboration between device makers, pharma developers, and health systems to develop evidence packages that demonstrate real-world benefit. Additionally, the competitive environment is opening to newer entrants focused on niche opportunities, such as battery longevity optimization, minimally invasive implant techniques, and adjunctive software services. Collectively, these shifts are steering the sector toward integrated solution models where device performance, clinician training, and service delivery converge to determine clinical and commercial success.
Observed supply chain realignments and procurement responses following tariff-driven cost and logistics pressures affecting components, manufacturing, and device availability
Recent tariff measures implemented in the United States have produced a tangible ripple effect across supply chains that support intrathecal pump manufacturing and distribution, with impacts observed across sourcing, procurement, and operational planning. Manufacturers that historically relied on cross-border component sourcing have had to re-evaluate supplier footprints in response to increased import costs and longer lead times. In some cases, this has accelerated the onboarding of alternative suppliers closer to key manufacturing hubs or prompted the requalification of legacy domestic suppliers to preserve continuity of production.
Procurement teams and hospital supply chains have adjusted purchasing strategies to mitigate near-term cost pressures, prioritizing inventory buffers and negotiating more flexible contractual terms with vendors. At the clinical delivery level, facilities have re-examined device selection criteria against total acquisition and servicing considerations, seeking devices with lower refill frequency or simplified maintenance protocols that reduce cumulative procedural burden. Regulatory compliance and customs procedures have also required tighter coordination between manufacturers and logistics partners to prevent delays in device availability. Taken together, these dynamics underscore the importance of supply chain resilience, diversified sourcing strategies, and operational contingency planning to maintain consistent access to intrathecal therapies for patients and providers.
Deep segmentation-driven insights linking pump types, therapeutic agents, care settings, and clinical indications to inform targeted clinical strategies and product design priorities
Segmentation analysis provides a structured lens to interpret clinical use patterns, procurement priorities, and product development focus across intrathecal therapy categories. Based on Pump Type, market is studied across External Pumps and Implantable Pumps, and each pump class follows distinct clinical pathways: external pumps are frequently used in trialing and short-term therapeutic scenarios, enabling rapid titration and reversible testing, while implantable pumps are favored for chronic administration where continuous, long-term control is required and device longevity, refill scheduling, and implantation logistics become central determinants of clinical suitability.
Based on Drug Type, market is studied across Baclofen, Local Anesthetics, and Opioids, and therapeutic selection is influenced by the underlying neurologic or pain condition, safety profile, and compatibility with pump delivery parameters. Baclofen remains the pharmacologic mainstay for severe spasticity due to its targeted action at spinal GABA receptors, while local anesthetics and opioids serve differentiated roles in managing localized nociceptive and neuropathic pain, each requiring tailored dosing regimens and monitoring strategies. Based on Therapy Area, market is studied across Pain Management and Spasticity Management. The Pain Management is further studied across Cancer Pain and Chronic Noncancer Pain. The Spasticity Management is further studied across Cerebral Palsy, Multiple Sclerosis, and Spinal Cord Injury. These therapeutic distinctions map to unique clinical pathways, with cancer pain often prioritizing rapid symptom control and palliative considerations, whereas chronic noncancer pain and spasticity conditions emphasize long-term functional outcomes, device tolerability, and integration with rehabilitation services.
Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, and each care setting imposes different operational requirements and value propositions. Ambulatory surgical centers may prioritize streamlined implantation protocols and rapid turnover, hospitals often require comprehensive perioperative support and complex case management, and specialty clinics emphasize multidisciplinary follow-up, titration expertise, and coordinated refill services. Together, these segmentation dimensions reveal where product design, service delivery, and stakeholder engagement must be aligned to meet the clinical and operational demands of diverse use cases.
Regional adoption dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape clinical access and manufacturing strategies
Regional dynamics exert a strong influence on clinical adoption patterns, regulatory approaches, and manufacturing strategies across intrathecal therapies. In the Americas, healthcare systems exhibit a mix of high-volume tertiary centers and a growing network of outpatient surgical facilities, and adoption is frequently shaped by reimbursement pathways, clinician training availability, and a strong emphasis on real-world evidence to support therapeutic choices. The Americas also house significant medtech manufacturing capability, which can facilitate closer coordination between development teams and clinical partners.
Europe, Middle East & Africa presents a heterogeneous environment where country-level regulatory frameworks and payer structures create varied adoption trajectories. In parts of Europe, centralized health technology assessment and long-standing specialty centers for neuromodulation support nuanced evidence development, whereas other jurisdictions within the region may emphasize cost-containment and centralized procurement strategies. Middle Eastern and African markets show pockets of high adoption in well-resourced centers alongside growing interest in capacity building, clinician training, and locally adapted care models.
Asia-Pacific encompasses a broad spectrum of health system maturity, with rapidly expanding clinical infrastructures in several markets, increasing local manufacturing investments, and growing clinical research activity. Regulatory harmonization initiatives and the scaling of specialty clinics are enabling broader patient access in many urban centers. Across all regions, stakeholders are increasingly focused on ensuring that device support networks, clinician education, and supply continuity are robust enough to sustain long-term therapy delivery.
How differentiated device features, integrated service models, and strategic partnerships are defining competitive advantage among manufacturers and new entrants in intrathecal therapy
Competitive positioning in the intrathecal therapy space is being defined by a mix of established medical device firms, specialized device innovators, and adjacent life sciences players seeking to expand into integrated therapy solutions. Leading organizations are investing in end-to-end value propositions that combine device hardware, software-enabled monitoring, and clinician education services to differentiate on total cost of care and long-term patient management. Strategic partnerships with pharmaceutical developers are also increasingly common, enabling coordinated development of device-drug combinations and shared clinical evidence initiatives.
New entrants are targeting niche technical improvements, such as refined catheter fixation systems, extended battery life, or simplified refill interfaces that reduce procedural complexity. Contract manufacturing organizations and regional suppliers are playing a larger role in enabling flexible production footprints, particularly where tariff pressures or logistics constraints have elevated the importance of nearshoring. Intellectual property portfolios that protect key delivery mechanisms and software algorithms are central competitive assets, while real-world evidence programs and registry participation are emerging as critical tools for demonstrating comparative performance and safety to clinicians and payers. Overall, companies that combine technical differentiation with robust service models and evidence generation are positioned to secure durable clinical partnerships.
Practical strategic priorities for device manufacturers and healthcare leaders to strengthen resilience, clinical value, and adoption of intrathecal therapies across care settings
Industry leaders should prioritize practical, patient-centered strategies that strengthen resilience, clinical value, and long-term adoption. First, supply chain diversification and nearshoring of critical components should be pursued to mitigate exposure to tariff-driven disruptions and to reduce lead time variability. Second, investment in device features that reduce clinical friction-such as longer refill intervals, simplified programming interfaces, and enhanced telemetry-will meaningfully improve adoption in both ambulatory and hospital settings.
Third, manufacturers and clinical leaders should collaborate to generate robust real-world evidence focused on functional outcomes, safety over longitudinal follow-up, and healthcare utilization metrics that resonate with payers. Fourth, embedding structured clinician training programs and certified centers of excellence models will accelerate safe adoption and improve consistency of patient outcomes. Fifth, consider flexible commercial models that align pricing and service delivery with demonstrated value, including outcome-linked contracting where feasible. Finally, continued attention to regulatory engagement and post-market surveillance will be essential to maintain trust, rapidly address safety signals, and support iterative device improvements that reflect clinician feedback and patient needs.
A robust multi-method research approach combining expert interviews, clinical literature review, regulatory analysis, and data triangulation to ensure reliable and actionable insights
The research underpinning this executive synthesis was developed through a multi-method approach that integrates primary stakeholder engagement with rigorous secondary evidence synthesis. Primary inputs included structured interviews with clinicians experienced in intrathecal therapy, procurement and supply chain professionals, regulatory specialists, and product development leaders. These conversations provided detailed insights into procedural workflows, device selection criteria, and operational barriers to adoption.
Secondary research encompassed a systematic review of peer-reviewed clinical literature, device regulatory filings, clinical guidelines, and device registries to contextualize clinical outcomes and safety profiles. Data triangulation was applied to reconcile differing perspectives and to validate recurring themes. Quality control procedures included cross-validation of interview insights against documented clinical evidence and regulatory records, and findings were peer-reviewed within the research team to ensure coherence and robustness. Throughout, the methodology emphasized transparency, reproducibility, and the synthesis of actionable intelligence tailored to decision-makers engaged in device development, clinical program design, and supply chain planning.
Synthesis of core conclusions emphasizing alignment of device innovation, clinician training, and supply chain resilience to sustain long-term intrathecal therapy delivery
Intrathecal pump therapies occupy a distinct clinical niche that demands coordinated attention to device performance, clinical training, and operational logistics. Advances in device engineering and the integration of remote monitoring are creating opportunities to improve patient outcomes while reshaping how care pathways are structured. At the same time, external pressures such as tariff-driven supply chain adjustments and evolving payer expectations are prompting stakeholders to re-evaluate sourcing, procurement, and evidence generation strategies.
The synthesis presented here underscores that successful adoption hinges on aligning product innovation with real-world clinical needs, investing in clinician education and service models, and building resilient supply chains capable of responding to policy and logistical shifts. Decision-makers who proactively address these dimensions can better position their organizations to deliver consistent, high-quality intrathecal care and to navigate the complex interplay of clinical, regulatory, and commercial forces that will influence long-term therapy sustainability.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of MRI compatible intrathecal pumps for enhanced imaging safety
- 5.2. Expansion of remote patient monitoring integration in intrathecal pump systems for real time therapy adjustments
- 5.3. Growing emphasis on minimally invasive refill and programmable drug delivery intrathecal pump designs
- 5.4. Increasing focus on opioid sparing pain management through targeted intrathecal drug delivery
- 5.5. Regulatory approvals driving market uptake of next generation rechargeable intrathecal pump technologies
- 5.6. Development of smart sensor enabled intrathecal pumps for automated dose control and complication detection
- 5.7. Pressure on cost effectiveness and reimbursement policies shaping intrathecal pump adoption in hospitals
- 5.8. Penetration of intrathecal pump therapy in emerging markets fueled by partnerships and local manufacturing
- 5.9. Expansion of intrathecal pump use beyond cancer pain into complex chronic pain syndromes such as failed back surgery and complex regional pain
- 5.10. Rapid uptake of intrathecal baclofen pumps for refractory spasticity in cerebral palsy and multiple sclerosis, driven by documented functional and quality of life improvements
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Intrathecal Pumps Market, by Pump Type
- 8.1. External Pumps
- 8.2. Implantable Pumps
- 9. Intrathecal Pumps Market, by Drug Type
- 9.1. Baclofen
- 9.2. Local Anesthetics
- 9.3. Opioids
- 10. Intrathecal Pumps Market, by Therapy Area
- 10.1. Pain Management
- 10.1.1. Cancer Pain
- 10.1.2. Chronic Noncancer Pain
- 10.2. Spasticity Management
- 10.2.1. Cerebral Palsy
- 10.2.2. Multiple Sclerosis
- 10.2.3. Spinal Cord Injury
- 11. Intrathecal Pumps Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Hospitals
- 11.3. Specialty Clinics
- 12. Intrathecal Pumps Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Intrathecal Pumps Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Intrathecal Pumps Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Medtronic plc
- 15.3.2. Flowonix Medical, Inc.
- 15.3.3. Tricumed Medizintechnik GmbH
- 15.3.4. Teleflex Inc.
- 15.3.5. Johnson & Johnson Services Inc.
- 15.3.6. B. Braun Melsungen AG
- 15.3.7. Baxter International Inc.
- 15.3.8. Fresenius Kabi AG
- 15.3.9. Terumo Corporation
- 15.3.10. Becton Dickinson and Company
- 15.3.11. Smiths Medical
- 15.3.12. Boston Scientific Corporation
- 15.3.13. Abbott Laboratories
- 15.3.14. Medallion Therapeutics, Inc.
- 15.3.15. Arrow International, Inc.
- 15.3.16. Durect Corporation
- 15.3.17. Zimmer Biomet Holdings, Inc.
- 15.3.18. Arthrex, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
